Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CABA 201

Drug Profile

CABA 201

Alternative Names: CABA-201

Latest Information Update: 19 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cabaletta Bio
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myositis; Systemic scleroderma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Myasthenia gravis; Myositis; Systemic lupus erythematosus; Systemic scleroderma
  • Phase I Pemphigus vulgaris

Most Recent Events

  • 14 Jun 2024 Adverse events and efficacy data from Phase-I/II RESET-Myositis trial in Myositis released by the Cabaletta Bio
  • 14 Jun 2024 Advese events and efficacy data from phase I/II trial in Systemic lupus erythematosus released by Cabaletta Bio (NCT06121297)
  • 03 Jun 2024 Cabaletta Bio initiates phase I/II clinical trial in Myasthenia gravis (lV) in USA (NCT06359041)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top